Risk factors for early morbidity and mortality of HIV-exposed uninfected infants

描述（由申请人提供）：每年有超过200万名儿童由艾滋病毒感染的妇女所生。随着在获得抗逆转录病毒疗法和预防母婴传播战略方面取得的进展，婴儿感染在博茨瓦纳这样的环境中已变得不常见。然而，这些接触艾滋病毒但未感染的婴儿的死亡风险仍然比未接触艾滋病毒的儿童高2至4倍，占博茨瓦纳5岁以下死亡人数的一半以上。尽管其巨大的公共卫生的重要性，这种死亡率差距的病因是未知的，战略，以减轻这种过度的死亡率在艾滋病毒暴露未感染（艾滋病毒欧盟）的婴儿还没有以前的研究。晚期孕产妇艾滋病毒疾病与保护性抗体转移减少和婴儿预后不良有关。如最近修订的卫生组织准则所赞同的，通过扩大使用产妇高效抗逆转录病毒疗法预防母婴传播来治疗产妇艾滋病毒，也可改善未感染婴儿的健康结果。然而，母亲HAART与早产、低出生体重和严重婴儿贫血的风险增加有关-所有这些都是死亡率增加的重要预测因素。利用独特的临床数据和样本，从博茨瓦纳哈佛艾滋病研究所伙伴关系的特征明确的队列，该项目将审查产妇HAART和其他因素对艾滋病毒-欧盟婴儿的整体健康的影响的关键问题。该项目有两个具体目标：1）通过汇总4个大队列的数据，确定博茨瓦纳2621名HIV-EU婴儿死亡或住院（包括HAART）的相关因素，2）确定婴儿对常见病原体的抗体水平降低是否与缺乏母体HAART以及HIV-EU婴儿死亡或住院有关。这些研究的结果可能会影响使用产妇HAART，疫苗接种策略和其他干预措施，以改善越来越多的艾滋病毒暴露，未感染婴儿的结果。此外，这些辅导项目是详细的职业发展计划的一部分，将为候选人提供成功过渡到独立调查员的知识，技能和经验。 公共卫生相关性声明（由申请人提供）：全世界有200万名儿童是由感染艾滋病毒的妇女所生。这些婴儿中的大多数不会感染艾滋病毒，但他们仍然是2-4岁 2岁时死亡的可能性是未感染艾滋病毒母亲所生婴儿的两倍。该项目旨在研究发生这种情况的原因，以制定预防这些死亡的战略。

DESCRIPTION (provided by applicant): Over two million children are born to HIV-infected women annually. With advances in access to antiretroviral therapy and strategies to prevent mother-to-child transmission (MTCT), infant infection has become uncommon in settings like Botswana. However, these HIV-exposed but uninfected infants remain at 2 to 4-fold greater risk of dying than matched HIV-unexposed children, accounting for more than half of all deaths before age 5 in Botswana. Despite its great public health importance, the etiology of this mortality gap is unknown and strategies to mitigate this excess mortality in HIV-exposed uninfected (HIV-EU) infants have not been previously studied. Advanced maternal HIV disease is associated with decreased transfer of protective antibodies and poor infant outcomes. Treatment of maternal HIV, through expanded use of maternal highly- active antiretroviral therapy (HAART) for prevention of MTCT, as endorsed by recently revised WHO guidelines, may also improve health outcomes of uninfected infants. However, maternal HAART is associated with increased risk of prematurity, low birth weight, and severe infant anemia- all important predictors of increased mortality. Utilizing unique clinical data and specimens from well-characterized cohorts at the Botswana Harvard AIDS Institute Partnership, the project will examine the critical question of the effect of maternal HAART and other factors on the overall health of HIV-EU infants. The project as two specific aims: 1) determine factors associated with death or hospitalization (including HAART) among 2621 HIV-EU infants in Botswana by pooling data from 4 large cohorts, and 2) determine if reduced infant antibody levels to common pathogens are associated with lack of maternal HAART, and with death or hospitalization in HIV-EU infants. The results of these studies could impact the use of maternal HAART, vaccination strategy, and other interventions to improve outcomes for the rising number of HIV-exposed, uninfected infants. In addition, these mentored projects are part of a detailed Career Development Plan that will provide the Candidate with the knowledge, skills, and experience to successfully transition to an independent investigator. Public Health Relevance Statement (provided by the applicant): Worldwide two million children are born to women with HIV. Most of these infants will not get HIV, but they are still 2-4 times more likely to die by 2 years of age than infants born to mothers without HIV. This project aims to study reasons why this happens with a goal of developing strategies to prevent these deaths.